SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.

Shenzhen Kangtai Biological Products Co., Ltd.

300601

CNE100002Q33

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 09/05/2024 BST			5-day change	1st Jan Change
20.81 ^CNY	-2.44%		+3.02%	-23.35%

04-26	Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-26	Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Shenzhen Kangtai Biological Products Co., Ltd. Announces Final Cash Dividend for the Year 2021, Payable on 2 June 2022

May 27, 2022 at 08:34 pm

Shenzhen Kangtai Biological Products Co., Ltd. announced final cash dividend of CNY 8.50000000 per 10 shares (tax included) for the year 2021, payable on 2 June 2022 and record date of June 1, 2022.

Latest news about Shenzhen Kangtai Biological Products Co., Ltd.

Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-26	CI
Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-26	CI
Kangtai Biological Forecasts Swing to Profit in 2023	01-10	MT
Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	26/10/23	CI
Kangtai Signs Deal to Distribute Varicella Vaccine in Pakistan, India	20/09/23	MT
Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	25/08/23	CI
Kangtai Biological Partners With Indian Drugmaker to Distribute Pneumococcal Vaccine	31/05/23	MT
Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23/04/23	CI
Tranche Update on Shenzhen Kangtai Biological Products Co., Ltd.'s Equity Buyback Plan announced on October 12, 2022.	15/03/23	CI
Shenzhen Kangtai Biological Products Co., Ltd.'s Equity Buyback announced on October 12, 2022 has closed with 3,581,600 shares, representing 0.32% for CNY 120.97 million.	12/03/23	CI
Shenzhen Kangtai Biological sees 2022 net loss on weaker COVID shot demand	10/01/23	RE
Tranche Update on Shenzhen Kangtai Biological Products Co., Ltd.'s Equity Buyback Plan announced on October 12, 2022.	03/01/23	CI
Shares in Chinese Pharma Companies Decline Amid Drop in Vaccination Rates	29/12/22	MT
Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	27/10/22	CI
Tranche Update on Shenzhen Kangtai Biological Products Co., Ltd.'s Equity Buyback Plan announced on October 12, 2022.	12/10/22	CI
Shenzhen Kangtai Biological Products Co., Ltd. commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on September 14, 2022.	12/10/22	CI
China's CanSinoBIO H1 revenue drops on weaker COVID shot demand	29/08/22	RE
UBS Adjusts Shenzhen Kangtai Biological Products’ Price Target to 66 Yuan From 72.50 Yuan, Keeps at Buy	22/08/22	MT
Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	18/08/22	CI
Shenzhen Kangtai Biological Products Co., Ltd. authorizes a Buyback Plan.	17/08/22	CI
Kangtai Biological Sees Up to 70% Profit Slump in H1	26/07/22	MT
UBS Adjusts Shenzhen Kangtai Biological Products' Price Target to 116 Yuan From 125 Yuan, Keeps at Buy	06/05/22	MT
Kangtai Biological’s 2021 Profit Surges 86% on Robust Sales	29/04/22	MT
Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	27/04/22	CI
Kangtai Biological’s Q1 Profit Seen Soaring 11-Fold on Strong Sales	15/04/22	MT

Chart Shenzhen Kangtai Biological Products Co., Ltd.

Duration

Period

Chart Shenzhen Kangtai Biological Products Co., Ltd.

More charts

Shenzhen Kangtai Biological Products Co. specialises in the research, development and marketing of human vaccines. Products include vaccines against hepatitis B, haemophilus influenzae type B, measles and rubella.

Sector

Pharmaceuticals

Calendar

31/05/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Shenzhen Kangtai Biological Products Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

20.81 CNY

Average target price

34.78 CNY

Spread / Average Target

+67.13%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.	-23.35%	3.22B
CSL LIMITED	-2.61%	89.08B
SAMSUNG BIOLOGICS CO.,LTD.	+3.55%	40.9B
BIOGEN INC.	-14.40%	32.25B
UCB	+55.89%	25.14B
BIOMARIN PHARMACEUTICAL INC.	-15.96%	15.39B
INCYTE CORPORATION	-15.50%	11.91B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-41.29%	11.89B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.75%	11.64B
SWEDISH ORPHAN BIOVITRUM AB	+7.87%	9.03B

Biopharmaceuticals